Q2 FY2027 results
| Metric | Result | Change |
|---|---|---|
| Revenue | $111 billion | up 8% |
| Adjusted EPS | $11.68 | up 18% |
| Operating Profit | $1.9 billion | up 13% |
| North American Pharmaceutical Revenue | $91.4 billion | up 6% |
| Oncology & Multispecialty Revenue | $15 billion | up 24% |
Guidance and outlook
- Raised fiscal 2027 adjusted earnings per diluted share guidance to $45.60 to $46.40.
- Anticipates full-year revenue growth of 6% to 10% and operating profit growth of 12% to 16%.
- Expects free cash flow of approximately $4.5 billion to $4.9 billion.
- Anticipates share repurchases of approximately $5 billion for fiscal 2027.
How management sounded
Positive (+7 on our -10 to +10 scale). Management raised full-year guidance and highlighted strong execution across all segments, despite acknowledging a dynamic policy environment. Management sounded more upbeat than on 48% of the 190 calls we cover; most companies sound positive on their own calls, so the comparison says more than the label.
Q&A summary
Acquisitions
Asked: How will the Precision Medicine Group and Option Care Health acquisitions impact reporting segments and margins?
Answer: Precision Medicine Group will report within the Oncology & Multispecialty segment and is expected to be accretive, while the Option Care Health investment will be accounted for via the equity method and reported in the Corporate segment.
340B Policy
Asked: How might potential 340B policy changes impact the business?
Answer: Management stated they do not anticipate a material financial impact and will continue to support customers regardless of the policy outcome.
North American Pharmaceutical Sustainability
Asked: Is the current growth in North American Pharmaceutical sustainable long-term?
Answer: Management emphasized the durability of the business, driven by broad-based growth in specialty products and GLP-1s, and noted that the long-term growth targets are not indicators of short-term variations.
Option Care Health Strategy
Asked: Is there an oncology overlay for the Option Care Health investment?
Answer: Management views the investment as complementary to their existing specialty and community-based care capabilities, allowing them to participate in the growing ambulatory infusion market.
What to watch before the next call
- Integration progress and synergy realization from the Precision Medicine Group acquisition.
- Regulatory approval and closing conditions for the Option Care Health investment.
- Impact of potential 340B policy changes and the evolving healthcare policy environment.
- Quarterly variability in GLP-1 medication demand and prior authorization volumes.
